Toxicity clinical trials

Explore recruiting toxicity clinical trials.

Recruiting toxicity studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Toxicity trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Phase 2 study of belantamab mafodotin in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma

Czechia

Therapeutic exploratory (Phase II) EU CTIS Study details

Phase II trial of acalabrutinib in combination with tafasitamab in patients with previously treated marginal zone lymphomas (MZL)

Italy, Austria

Therapeutic exploratory (Phase II) EU CTIS Study details

Prospective, multicentre phase II study of de-escalation of primary chemoradiotherapy of squamous cell carcinoma of oropharynx (OPC) associated with human papilloma virus (HPV)

Slovakia

Therapeutic exploratory (Phase II) EU CTIS Study details

A randomized non-comparative phase II study of Maintenance therapy with OSE2101 plus FOLFIRI, or FOLFIRI after induction therapy with FOLFIRINOX in patients with locally advanced or metastatic Pancreatic ductal adenocarcinoma.

France

Therapeutic exploratory (Phase II) EU CTIS Study details

AD ASTRA (Androgen Deprivation with Apalutamide and STereotactic RAdiotherapy)

Slovakia

Therapeutic exploratory (Phase II) EU CTIS Study details

Phase I/IIa multicentre phase I/IIa study of infusion of autologous peripheral blood T lymphocytes expanded and genetically modified using Sleeping Beauty family transposons to express a chimeric antigenic receptor with anti-CD19 specificity conjugated to the 4-1BB co-stimulatory and signal-transduction region CD3z and huEGFRt (TranspoCART19) in patients with relapsed or refractory B-cell lymphoma.

Spain

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Toxicity trials by city

Toxicity in Toronto Toxicity in Vancouver Toxicity in Montreal Toxicity in Calgary Toxicity in Edmonton Toxicity in Ottawa Toxicity in Winnipeg Toxicity in Quebec City Toxicity in Hamilton Toxicity in Kitchener Toxicity in London Toxicity in Halifax Toxicity in New York Toxicity in Los Angeles Toxicity in Chicago Toxicity in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease